Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma

KIMMTRAK Reimbursement Agreement - KIMMTRAK (tebentafusp) has been recommended for funding through the NHS in England by NICE for the treatment of HLA-A02:01-positive adults with unresectable or metastatic uveal melanoma [1] - This recommendation overturns the initial negative decision by NICE in May 2023, which the company successfully appealed in December 2023 [2] - KIMMTRAK is now funded on the NHS in England as of 02 December 2024 [4] Impact on Patients and Medical Community - KIMMTRAK is the first therapy to improve survival for HLA-A02:01-positive metastatic or unresectable uveal melanoma, marking a major step forward for patients and their families [3] - Uveal melanoma is a very rare form of melanoma requiring different clinical management, and the option to prescribe tebentafusp represents a significant advancement for patients [3] - The recommendation highlights the power of collaboration between patients, advocates, and medical experts in advancing care for ocular melanoma [4] About KIMMTRAK and Uveal Melanoma - KIMMTRAK is a novel bispecific protein targeting gp100, a lineage antigen expressed in melanocytes and melanoma, developed using Immunocore's ImmTAC technology platform [6] - Uveal melanoma is a rare and aggressive form of melanoma affecting the eye, with up to 50% of patients developing metastatic disease and historically having no approved treatment until KIMMTRAK [5] - KIMMTRAK is indicated as monotherapy for HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in multiple regions, including the US, EU, Canada, Australia, and the UK [7] Immunocore's Technology and Pipeline - Immunocore's proprietary TCR technology generates ImmTAC molecules, designed to redirect the immune system to recognize and kill cancerous cells, with potential applications in hematologic and solid tumors [9] - The company is a commercial-stage biotechnology firm pioneering the development of TCR bispecific immunotherapies (ImmTAX) for cancer, autoimmune diseases, and infectious diseases [10] - Immunocore has nine active clinical and pre-clinical programs in oncology, infectious diseases, and autoimmune diseases, with KIMMTRAK being its most advanced oncology TCR therapeutic [10]